Shares of Bio-Techne Corp. slipped 4.01% to $48.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.01% to 6,699.38 and the Dow ...

Bio-Techne TECH continues to expand its portfolio and enter adjacent markets via acquisitions and strategic investments. Strength in international markets underscores the company’s growth potential.

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bio-Techne (TECH) is back in focus after institutional ...

MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the ...

Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers. Innovation has the potential to improve preclinical research by reducing ...

Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...